Loading
JPXHealthcareMedical - Diagnostics & Research
Latest quote
¥3,367
−¥21.00 · -0.62%
Established in 1950 and headquartered in Tokyo, Japan, H.U. Group Holdings, Inc. (formerly Miraca Holdings Inc. until its rebranding in July 2020) provides an extensive array of laboratory testing products and services through its subsidiaries across Japan. The company delivers diagnostic testing and associated services to medical facilities, supports self-medication initiatives, and conducts testing for food, environmental samples, and cosmetic products. Additionally, it offers testing solutions tailored for corporate health insurance programs. The group is deeply involved in the research, development, manufacturing, and commercialization of in vitro diagnostic devices. Its product lineup features the LUMIPULSE, an automated chemiluminescent enzyme immunoassay system that supplies reagents for the detection of infectious diseases, various cancers, and lifestyle-related conditions to medical institutions and diagnostic centers. H.U. Group also produces the ESPRINE series of rapid diagnostic kits for ailments such as influenza, hepatitis B, and the novel coronavirus, alongside supplying essential ingredients for test drugs. Beyond diagnostics, the company offers crucial support services for hospital administration, including assistance during surgical and endoscope procedures, inspection and maintenance of medical equipment, and in-hospital logistics and transportation management. Furthermore, it addresses the elderly care market by renting and selling specialized equipment and supplies, and by providing in-home nursing care services.
Latest quote
¥3,367
−¥21.00 · -0.62%
Regular session · JST · Market data may be delayed.
Established in 1950 and headquartered in Tokyo, Japan, H.U. Group Holdings, Inc. (formerly Miraca Holdings Inc. until its rebranding in July 2020) provides an extensive array of laboratory testing products and services through its subsidiaries across Japan. The company delivers diagnostic testing and associated services to medical facilities, supports self-medication initiatives, and conducts testing for food, environmental samples, and cosmetic products. Additionally, it offers testing solutions tailored for corporate health insurance programs. The group is deeply involved in the research, development, manufacturing, and commercialization of in vitro diagnostic devices. Its product lineup features the LUMIPULSE, an automated chemiluminescent enzyme immunoassay system that supplies reagents for the detection of infectious diseases, various cancers, and lifestyle-related conditions to medical institutions and diagnostic centers. H.U. Group also produces the ESPRINE series of rapid diagnostic kits for ailments such as influenza, hepatitis B, and the novel coronavirus, alongside supplying essential ingredients for test drugs. Beyond diagnostics, the company offers crucial support services for hospital administration, including assistance during surgical and endoscope procedures, inspection and maintenance of medical equipment, and in-hospital logistics and transportation management. Furthermore, it addresses the elderly care market by renting and selling specialized equipment and supplies, and by providing in-home nursing care services.
Regular session · JST · Market data may be delayed.
Established in 1950 and headquartered in Tokyo, Japan, H.U. Group Holdings, Inc. (formerly Miraca Holdings Inc. until its rebranding in July 2020) provides an extensive array of laboratory testing products and services through its subsidiaries across Japan. The company delivers diagnostic testing and associated services to medical facilities, supports self-medication initiatives, and conducts testing for food, environmental samples, and cosmetic products. Additionally, it offers testing solutions tailored for corporate health insurance programs. The group is deeply involved in the research, development, manufacturing, and commercialization of in vitro diagnostic devices. Its product lineup features the LUMIPULSE, an automated chemiluminescent enzyme immunoassay system that supplies reagents for the detection of infectious diseases, various cancers, and lifestyle-related conditions to medical institutions and diagnostic centers. H.U. Group also produces the ESPRINE series of rapid diagnostic kits for ailments such as influenza, hepatitis B, and the novel coronavirus, alongside supplying essential ingredients for test drugs. Beyond diagnostics, the company offers crucial support services for hospital administration, including assistance during surgical and endoscope procedures, inspection and maintenance of medical equipment, and in-hospital logistics and transportation management. Furthermore, it addresses the elderly care market by renting and selling specialized equipment and supplies, and by providing in-home nursing care services.
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 247.36B JPY | 243.03B JPY | 236.95B JPY | 260.91B JPY | 272.94B JPY |
| Cost of goods sold | 176.6B JPY | 175.83B JPY | 173.72B JPY | 170.98B JPY | 161.15B JPY |
| Gross profit | 70.77B JPY | 67.2B JPY | 63.24B JPY | 89.92B JPY | 111.8B JPY |
| Research and development | — | 10.89B JPY | 11.26B JPY | 9.56B JPY | 7.28B JPY |
| Selling, general, and administrative | 65.99B JPY | 48.08B JPY | 50.05B JPY | 51.57B JPY | 51.18B JPY |
| Operating expenses | 65.99B JPY | 64.56B JPY | 67.28B JPY | 66.54B JPY | 61.31B JPY |
| Interest income | 402M JPY | 508M JPY | 454M JPY | 242M JPY | 45M JPY |
| Interest expense | 686M JPY | 591M JPY | 399M JPY | 369M JPY | 395M JPY |
| Depreciation and amortization | 21.76B JPY | 20.75B JPY | 20.87B JPY | 19.69B JPY | 14.63B JPY |
| Operating income | 4.78B JPY | 2.64B JPY | −4.04B JPY | 23.38B JPY | 50.49B JPY |
| Net income | 6.82B JPY | 2.76B JPY | −7.55B JPY | 15.68B JPY | 29.6B JPY |
Company facts updated Sep 12, 2026.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core TOPIX ETF1475.T560.71M0.02%2.91T JPY0.05%¥413.5-0.48%
Vanguard Total International Stock ETFVXUS17.5M0.00%646.2B USD0.05%$87.14+1.00%
Vanguard FTSE Developed Markets ETFVEA11.67M0.00%315B USD0.03%$72.69+1.07%
iShares Core MSCI EAFE ETFIEFA7.81M0.00%193.07B USD0.07%$99.50+1.00%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS4.69M0.03%13.6B USD0.06%$158.56+0.72%
iShares MSCI EAFE Small-Cap ETFSCZ4.22M0.03%12.89B USD0.40%$86.09+0.87%
iShares Core MSCI Total International Stock ETFIXUS2.99M0.00%59.9B USD0.07%$97.22+0.98%
Schwab International Small-Cap Equity ETFSCHC2.65M0.05%5.7B USD0.06%$50.72+0.63%iShares Core TOPIX ETF1475.TVanguard Total International Stock ETFVXUSVanguard FTSE Developed Markets ETFVEAiShares Core MSCI EAFE ETFIEFAVanguard FTSE All-World ex-US Small-Cap ETFVSSiShares MSCI EAFE Small-Cap ETFSCZiShares Core MSCI Total International Stock ETFIXUSSchwab International Small-Cap Equity ETFSCHCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
